This study aimed to analyse the association of HLA-B alleles other than -B51 with Behçet's disease (BD).
Introduction
Behçet's disease is an inflammatory disorder characterized by recurrent oral and genital aphthous ulceration, uveitis, and skin lesions. 1 It is now recognized as a systemic vasculitis also affecting joints, all types and sizes of blood vessels, lungs, central nervous, and gastrointestinal systems.
The aetiology of Behçet's disease is unknown. It has been claimed that immunologic abnormalities triggered by some microbial agents or other environmental factors in genetically susceptible individuals play an important role in the development of the disease. 2 An association between Behçet's disease and HLA-B51 has been regarded as the strongest evidence for involvement of genetic factors in the pathogenesis, and this association has been confirmed in different ethnic groups with varying strength. [3] [4] [5] [6] [7] [8] [9] By molecular genetic analysis of the major histocompatibility complex (MHC) region, it has been suggested that HLA-B51 might not be pathogenic itself, but indicate linkage disequilibrium with a putative susceptibility gene very close to the HLA-B locus. [10] [11] [12] [13] [14] Several novel genes have been identified by investigation of the region between the tumor necrosis factor (TNF) and HLA-B loci. However, HLA-B51 has so far shown the strongest association with Behçet's disease, and a putative Behçet's disease susceptibility gene located centromeric to HLA-B has yet to be isolated. 13, 14 HLA class I molecules are primarily involved in the presentation of self or viral antigens to CD8 + T cells. Another function of HLA class I molecules has recently been described by the identification of a new family of receptors expressed mainly by natural killer (NK) cells, and also CD8
+ cells, and ␥␦ T cell receptor (TCR) + cells. These receptors, killer immunoglobulin-like receptors (KIR), bind to conserved epitopes shared by different allellic groups of HLA class I molecules, and engagement of these receptors has been shown to be associated with selective inhibition of NK cell or T cell-mediated cytotoxicity. [15] [16] [17] [18] We aimed to search for weaker associations of other HLA-B alleles with Behçet's disease. However, since HLA-B51 has been strongly associated with Behçet's disease, relative contibutions of other HLA-B alleles are possibly being masked and cannot easily be determined using classical methods. For that reason, we used the relative predispositional effects (RPE) method, 19 , which was developed to identify small predispositional or protective effects of different alleles using the sequential comparison of allele frequencies. This method has previously been used for the identification of relative effects of different HLA alleles in diabetes mellitus, Grave's disease and rheumatoid arthritis.
We also aimed to test the hypothesis that -B51 association with Behçet's disease might be related to an interaction with selected KIR molecules on NK or other cytotoxic T cells by investigating the frequency of HLA-B alleles sharing the same KIR binding sequence with -B51. We compared the frequencies of the HLA-B alleles with this shared sequence in the patients and controls, and also repeated the RPE analysis after classification of the HLA-B alleles according to the presence or absence of the shared sequence.
Results
Comparison of the phenotypic frequencies of HLA-B alleles in this group of Turkish patients with Behçet's disease and the matched healthy controls confirmed the strong association of B*51 with Behçet's disease (Table 1) . B*07, B*18 and B*52 alleles showed a negative association with Behçet's disease. However, when these results were corrected for the comparison of 30 alleles, statistical significance of all HLA-B associations except B*51 disappeared.
The distribution of HLA-B alleles in Behçet's disease patients was found to differ from the distribution in controls when compared using a 2 test ( Table 2) . As expected B*51 provided the strongest evidence of a difference (adjusted residual 6.8). After deletion of B*51 alleles (n = 127 in patients and n = 56 in controls), there was no clear evidence of a difference in the distribution of the remaining alleles (P = 0.06), although the B*15 allele showed the greatest difference (adjusted residual 2.8). HLA-B alleles reacting with sequence-specific oligonucleotide probe 23, which corresponds to the KIR binding site of B*51, were found to be positive in 127 Behçet's disease patients (73%) and 90 controls (47%) (odds ratios (OR) = 3.03, 95% confidence intervals (CI) 2-4.7, P Ͻ 0.0001). The overall comparison of the allele frequencies of HLA-B alleles with this sequence in Behçet's disease patients and controls using a 2 test was also significantly different (48% and 31% respectively, 2 = 21, 1 df, P Ͻ 0.001).
We repeated the RPE analysis after separating HLA-B alleles carrying this sequence into distinct alleles within a broad-type allele group, such as B*15S for all −B*15 alleles with this sequence and −B*15x for the rest, which increases the number of alleles to 34 (Table 3) . After the deletion of B*51 (B*51S), which showed the strongest difference, from the Behçet's disease patients and controls, overall distribution of the alleles was still significantly different (Table 4) . B*27S (B*2702), the only B*27 allele sharing this sequence, showed the second highest deviation in the patient group (adjusted residual 3.0). After the deletion of this allele (n = 8 in patients and n = 1 in controls), there was no further evidence of a difference between patients and controls (P = 0.08).
The frequencies of the B*2702 allele among B*27 positive Behçet's disease patients and controls showed a significant difference. Seven out of 11 (63.6%) B*27 positive Behçet's disease patients were carrying B*2702, compared with only one of 13 (7.7%) healthy controls (OR = 21.0, 95% CI 1.9-227.3, P = 0.008). Two of the Behçet's disease patients were found to be homozygous for B*2702.
Discussion
This study confirmed the strong association of HLA-B*51 with Behçet's disease, and also revealed only B*2702 as a further HLA-B allele associated with Behçet's disease by the RPE analysis.
Weak associations of HLA-B antigens other than −B51 with Behçet's disease have been reported previously and there are similarities between our results and findings in Japanese patients. 4 Mizuki and colleagues' investigation of HLA-B antigens in 81 Japanese patients revealed -B7 as the most prominent negatively associated antigen, and the -B62 antigen showed a weak association with Behçet's disease in HLA-B51 negative Japanese patients. The HLA-B62 antigen defined by serology is encoded mainly by HLA-B*1501 in Asians. 23 We similarly observed a decrease of B*07 and an increase of B*15 alleles in Turkish patients, although these differences did not reach statistical significance.
The consistency of the strong association of HLA-B51 and similar weaker positive and negative associations of some other HLA-B alleles with Behçet's disease in different ethnic groups supports the hypothesis that HLA-B alleles may play a direct role in the pathogenesis of Behçet's disease. Several mechanisms of action for HLA-51, including molecular mimicry with retinal antigens or as a factor causing neutrophil activation have been suggested.
2,24,25 HLA-B51 transgenic mice did not develop any Behçet's disease manifestations, but showed increased superoxide generation from neutrophils compared with non-transgenic or HLA-B35 transgenic animals. 25 A different pathogenic mechanism for the association of HLA-B51 with Behçet's disease might be suggested based on our finding of increased B*2702 allele frequency in the patients. Only B*2702 of the B*27 alleles shares a sequence with B*51 corresponding to the positions 77-83 in the ␣1-helix of HLA-B molecule. This shared sequence has been shown to be the binding site of KIR3DL1 (NKB1) and associated with selective inhibition of NK cell cytotoxicity. [15] [16] [17] 26 An expansion of CD8 + cells, ␥␦ TCR + cells and NK cells in patients with Behçet's disease was reported previously. [27] [28] [29] [30] [31] An impairment in the regulation of KIR-HLA class I interaction on NK and other cytotoxic T cells may contribute to the pathogenesis of Behçet's disease. It is also noteworthy that the same peptide sequence has been shown to exhibit immunosuppressive properties in rodents and humans. 32, 33 Identification of no HLA-B alleles other than B*2702, both carrying the same B*51 KIR-binding sequence and associated with Behçet's disease, makes this hypothesis less likely. On the other hand, it has been reported that binding of KIR is dependent on peptide as well as the class I molecule on the target cell. 26, 34, 35 Conformational changes in class I molecules after binding of certain peptides may influence its KIR binding specificity, and it may be an explanation for the association of only B*2702 with Behçet's disease.
Population stratification might be an alternative explanation for the selective increase of HLA-B*2702 allele in Behçet's disease. The frequency of B*2702 allele increases from the Northern European populations towards the Middle Eastern and African populations. 36 Undetectable population characteristics in the patient and so-called matched control groups might also have caused this weak association.
In conclusion, this study reveals a weak association of B*2702, the only B*27 allele carrying the same KIR binding sequence with B*51, with Behçet's disease. The possiblity of interaction of this sequence in the pathogenetic process of Behçet's disease warrants further investigation.
Materials and methods

Patients
The study group consisted of 174 consecutive patients with Behçet's disease (101 male, 73 female) followed at the Behçet's Disease Outpatient Clinic of the Division of Rheumatology, Istanbul School of Medicine. All patients met the International Study Group criteria for the classification of Behçet's disease 37 and gave a written consent prior to blood collection. A group of 191 ethnically matched non-related healthy volunteers were used as controls. These controls were recruited from individuals working within the Medical School Campus and none of them described a positive medical history including Behçet's disease.
HLA typing
The genomic DNA was isolated from peripheral blood mononuclear cells by using standard methods. Broadtype genotyping of HLA-B alleles was performed by the amplification of exon 2-intron 2-exon 3 using polymerase chain reaction (PCR) and hybridization with sequence specific oligonucleotide probes (SSOP) according to the protocols of the XIIth International HLA Workshop. 38, 39 NK cell immunoglobulin-like KIRs bind to the ␣1-helix of the HLA-B molecule at positions 77-83. One of the oligonucleotide probes (namely, 23) selects the sequence of the HLA-B*51 gene corresponding to positions 77-82 of the ␣1-helix. 38 We used this probe to detect the HLA-B alleles sharing this sequence of B*51 (see Appendix) among the HLA molecules with five different Bw4 motifs.
Statistical analysis
The phenotype frequencies of HLA-B alleles in the patient and the healthy control groups were compared For the RPE analysis, firstly the overall distribution of HLA-B alleles in Behçet's disease patients was compared with the distribution in the ethnically-matched controls using a 2 test. If there was evidence of a difference between patients and controls at the 5% significance level, the allele showing the strongest evidence of a difference, as measured by the adjusted residual, was identified. This allele was removed from the contingency table and distributions of the remaining alleles were compared. The process was repeated until there was no further evidence of a difference in distribution between patients and controls. Because of the small frequencies of many alleles, P-values were obtained by Monte-Carlo (MC) simulation. Statistical analyses were carried out using SPSS for Windows Release 9.0.1.
